cellectis.com (CLLS) Cash Funds per Single Share

Symbol and logo of brand Cellectis (CLLS)

Geopolitical risks and the fragmentation of data laws are forcing Cellectis S.A. (CLLS) to rely on a powerful alliance with AstraZeneca and TALEN technologies, which is confirmed by the cash position per share chart. The value of 2.32 determines the current status of the liquidity parameter. Completing the picture is the company's status as a pioneer of allogeneic CAR-T systems, which make express therapy accessible to a wide range of patients.

CLLS cellectis.com: Cash per Single Share in the range 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for cellectis.com (CLLS)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:CLLS (Cellectis SA)
Finished products of Cellectis S.A.

Outsourcing vector production and testing allows Cellectis S.A. (CLLS) to optimize expenses by focusing on gene editing. Current fluctuations in cash per share at 2.32 reflect the business's real-time liquid reserve per share without reporting delays, which determines the company's financial autonomy and its ability to sustain development during periods of market volatility.